ArticleDiabetes, obesity & metabolism2017

Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Ronald Goldenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.